Abstract:Precision in genetic modeling of oncogene-driven cancer is crucial for comprehending disease pathology. Traditionally, models focused on protein expression through open-reading-frame (ORF) transgenes. This approach overlooks post-transcriptional regulation in endogenous mRNAs, which include noncoding elements like 5' and 3' UTRs and introns. All patient oncogene mRNAs encompass these elements, and grasping the collective impact of noncoding and protein coding components may revolutionize our comprehension of cancer origins.Neuroblastoma (NB) is the most common extracranial solid tumor in children. Genetic amplification of MYCN (MA) in NB results in very high mRNA levels and drives poor prognosis. MYCN mRNA is targeted by multiple microRNAs, including let-7. We previously demonstrated that in MA disease the 3' UTR of MYCN can sequester let-7, inhibiting its function. MYCN mRNA thus also influences genetic patterning in NB by relieving the selective pressure to lose chromosome arms harboring let-7 loci, an event frequent in MYCN non-amplified NB but exceedingly rare in MA disease. This work established for the first time that noncoding mRNA elements within an oncogenic mRNA can itself contribute to disease pathology. To further understand the roles of noncoding elements within MYCN mRNA, we generated BALB/c 3T3 fibroblasts and murine Neuro-2a cells that express the following transgenes: 1.MYCN-ORF: expresses only MYCN open reading frame sequence.2.MYCN-GL: intact genetic locus of MYCN, expresses full length MYCN mRNA.3.M/GFP-GL: variant of #2 where MYCN protein coding sequences are replaced by EGFP. All three constructs demonstrated significantly enhanced in vitro proliferation compared to GFP control cells. Notably, cells expressing MYCN-GL exhibited best growth in both cell types, despite possessing an intact 3'UTR. Unexpectedly, M/GFP-GL cells demonstrated comparable growth to MYCN-ORF in 3T3s and significantly outperformed MYCN-ORF in Neuro-2a cells. This observation not only validates our prior research on the oncogenic role of the MYCN 3' UTR but also extends it by revealing direct contributions to growth advantages, occasionally surpassing even MYCN protein. Syngeneic animal studies mirrored these trends, with MYCN-GL and M/GFP-GL inducing nearly 100% tumor incidence, surpassing the 57% incidence associated with MYCN-ORF. Tumors induced by MYCN-GL and M/GFP-GL were more than twice the size of those induced by MYCN-ORF. These observations underscore that full-length MYCN mRNA, encompassing all noncoding elements, serves as a more potent driver of cellular growth and oncogenicity than only MYCN protein expression. These findings have exciting implications for understating neuroblastoma pathology and genetic patterns, with broader implications for other oncogene-driven cancers. We are currently generating transgenic mouse models based on the above three constructs. Citation Format: Vishwa Patel, Lorraine Rana Benhamou, Dr. John T. Powers. Noncoding elements of MYCN mRNA are powerful drivers on oncogenicity in neuroblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 153.

Expression of NLRR3 Orphan Receptor Gene is Negatively Regulated by MYCN and Miz-1, and Its Downregulation is Associated with Unfavorable Outcome in Neuroblastoma

Nlrr1 Enhances Egf-Mediated Mycn Induction In Neuroblastoma And Accelerates Tumor Growth In Vivo

Unfavorable Neuroblastoma Prognostic Factor NLRR2 Inhibits Cell Differentiation by Transcriptional Induction Through JNK Pathway.

Abstract 5254: NLRR family proteins play distinct roles in deciding cell fate and affect the clinical outcome in neuroblastomas

Data from NLRR1 Enhances EGF-Mediated <i>MYCN</i> Induction in Neuroblastoma and Accelerates Tumor Growth <i>In Vivo</i>

Collaborative ISL1/GATA3 interaction in controlling neuroblastoma oncogenic pathways overlapping with but distinct from MYCN.

L3MBTL2 maintains MYCN-amplified neuroblastoma cell proliferation through silencing NRIP3 and BRME1 genes

NLRR1 is a Potential Therapeutic Target in Neuroblastoma and MYCN-Driven Malignant Cancers

Neuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma

N-MYC promotes cell proliferation through a direct transactivation of neuronal leucine-rich repeat protein-1 ( NLRR1 ) gene in neuroblastoma

METTL3/MYCN cooperation drives neural crest differentiation and provides therapeutic vulnerability in neuroblastoma

Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma

HMGB3 is Associated With an Unfavorable Prognosis of Neuroblastoma and Promotes Tumor Progression by Mediating TPX2

Comprehensive analysis and validation reveal potential MYCN regulatory biomarkers associated with neuroblastoma prognosis

Downregulation of MEG3 Promotes Neuroblastoma Development Through FOXO1-mediated Autophagy and Mtor-Mediated Epithelial-Mesenchymal Transition.

Downregulation of MEG3 and Upregulation of EZH2 Cooperatively Promote Neuroblastoma Progression.

The Long Noncoding RNA Lncnb1 Promotes Tumorigenesis by Interacting with Ribosomal Protein RPL35

Abstract 153: Noncoding elements of MYCN mRNA are powerful drivers on oncogenicity in neuroblastoma

27 MRP3/MRP3(ABCC3/ABCC3) is up-regulated by TNF α via (cholesterol 7 α hydroxylase promoter factor (CPF) and is hepatoprotective in obstructive cholestasis

Downregulation of ABLIM3 confers to the Metastasis of Neuroblastoma via Regulating the Cell Adhesion Molecules Pathway

Inhibition of OCT4 binding at the MYCN locus induces neuroblastoma cell death accompanied by downregulation of transcripts with high-open reading frame dominance